Breaking News

Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome

Quoin Pharmaceuticals, Inc.

Quoin Anticipates Initiating Scientific Screening in Q2 2022

ASHBURN, Va., March 15, 2022 (World NEWSWIRE) — Quoin Prescription drugs Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical enterprise targeted on exceptional and orphan illnesses, right now announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted an Investigational New Drug (IND) software to the U.S. Food items and Drug Administration (Food and drug administration) for QRX003, the Company’s investigational solution for Netherton Syndrome, a rare and devastating genetic disease for which there is at this time no accessible remedy or treatment.

QRX003 is a topical lotion, formulated with a proprietary shipping and delivery technological know-how, and incorporates a broad-spectrum serine protease inhibitor, whose system of action is intended to perform the function of a precise protein, named LEKTI. The absence of LEKTI in Netherton sufferers prospects to too much skin shedding resulting in a extremely porous and compromised pores and skin barrier. Day-to-day application of QRX003 could potentially lead to advancement in skin architecture and restoration of the skin’s barrier qualities, resulting in considerably improved quality of lifetime for patients with Netherton Syndrome.

“This is an essential milestone for Quoin, and we’d like to thank everyone who participated in the preparation of the IND submission. We seem ahead to initiating scientific tests of QRX003 in this very underserved individual populace,” mentioned Dr. Michael Myers, Main Govt Officer of Quoin.

About Netherton Syndrome

Netherton Syndrome, a form of Ichthyosis, is a unusual, hereditary skin disorder brought about by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Kind 5) that qualified prospects to significant skin barrier flaws and recurring infections, as well as a pronounced predisposition to allergic reactions, asthma, and eczema. Sufferers also often go through from critical dehydration, chronic skin irritation and stunted development.

Presently, there is no overcome for Netherton Syndrome, nor are there any permitted therapeutic treatment plans.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is an rising specialty pharmaceutical corporation targeted on acquiring and commercializing therapeutic products and solutions that take care of exceptional and orphan disorders. We are committed to addressing unmet medical requires for sufferers, their people, communities and treatment groups. Quoin’s ground breaking pipeline includes a few products and solutions in development that collectively have the likely to goal a wide amount of exceptional and orphan indications, including Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and other folks. For a lot more information, go to: www.quoinpharma.com.

Cautionary Note Regarding Ahead Searching Statements

The Company cautions that statements in this push release that are not a description of historic specifics are forward-hunting statements inside of the which means of the Private Securities Litigation Reform Act of 1995. Forward-hunting statements could be discovered by the use of words and phrases referencing future functions or circumstances such as “expect,” “intend,” “program,” “foresee,” “believe,” and “will,” among other folks. Since these statements are topic to pitfalls and uncertainties, precise results could differ materially from individuals expressed or implied by these ahead-on the lookout statements. These ahead-searching statements are primarily based on the Company’s current anticipations and entail assumptions that may possibly by no means materialize or may perhaps establish to be incorrect. Genuine benefits and the timing of situations could vary materially from people expected in this kind of ahead-seeking statements as a final result of a variety of hazards and uncertainties. More in-depth facts about the challenges and uncertainties influencing the Business is contained less than the heading “Hazard Factors” included in the Company’s Annual Report on Kind 20-F submitted with the SEC on March 29, 2021, and in other filings the Organization has produced and may make with the SEC in the long term. One particular should not location undue reliance on these ahead-looking statements, which talk only as of the day on which they were being designed. For the reason that these kinds of statements are subject matter to risks and uncertainties, actual results may possibly vary materially from those expressed or implied by these ahead-wanting statements. The Business undertakes no obligation to update these statements to reflect activities that occur or conditions that exist after the date on which they have been created, besides as may possibly be required by regulation.

For further info, speak to:

Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
[email protected]

Trader Relations
PCG Advisory
Stephanie Prince
[email protected]
(646) 863-6341